Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Oberg
K
K
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden.
Akerström
G
G
Rindi
G
G
Jelic
S
S
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D003603:Cytotoxins / Q000627:therapeutic use; D004621:Embolization, Therapeutic; D005060:Europe / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D013502:General Surgery; D006801:Humans; D015994:Incidence; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D009362:Neoplasm Metastasis / Q000628:therapy; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D018570:Risk Assessment; D020123:Sirolimus / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D003603:Cytotoxins; D016898:Interferon-alpha; D013004:Somatostatin; D020123:Sirolimus